Liu Xiaozhou, Zhou Xing, Xu Haidong, He Zhiwei, Shi Xin, Wu Sujia
Department of Orthopedics, Jinling Hospital, School of Medicine, Nanjing University , Nanjing China .
DNA Cell Biol. 2017 Sep;36(9):775-780. doi: 10.1089/dna.2017.3750. Epub 2017 Aug 4.
Osteosarcoma (OS) is a bone malignancy with high incidence. The underlying molecular mechanisms that are associated with the development of OS need further investigation. In this study, we showed that SLC34A2, a member of the solute carrier gene family, was significantly downregulated in OS patients and cell lines. Overexpression of SLC34A2 inhibited the proliferation, migration, and invasion of OS cells. Mechanistically, we found that SLC34A2 interacted with PTEN, and inactivated the PI3K/AKT signaling pathway. Collectively, our results demonstrated that SLC34A2 plays important roles in regulating the cancer cell growth of OS. The downregulation of SLC34A2 in OS patients suggested that it might be a promising target in the diagnosis and therapy of OS.
骨肉瘤(OS)是一种高发的骨恶性肿瘤。与骨肉瘤发生相关的潜在分子机制需要进一步研究。在本研究中,我们发现溶质载体基因家族成员SLC34A2在骨肉瘤患者和细胞系中显著下调。SLC34A2的过表达抑制了骨肉瘤细胞的增殖、迁移和侵袭。机制上,我们发现SLC34A2与PTEN相互作用,并使PI3K/AKT信号通路失活。总体而言,我们的结果表明SLC34A2在调节骨肉瘤癌细胞生长中起重要作用。骨肉瘤患者中SLC34A2的下调表明它可能是骨肉瘤诊断和治疗中有前景的靶点。